Scaffolds for microtubule inhibition through extensive modification of the epothilone template

Angewandte Chemie - International Edition

Volumn 44, Issue 45, 2005, Pages 7469-7473

  Cachoux, Frédéric ^a,c   Isarno, Thomas ^a,d   Wartmann, Markus ^b   Altmann, Karl Heinz ^a  

^a ETH ZURICH   (Switzerland)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Prestwick Chemical Inc   (France)

^d Carbogen AG   (Switzerland)

Author keywords

Antitumor agents; Drug design; Epothilones; Microtubule stabilizers; Natural products; Total synthesis

Indexed keywords

ANTITUMOR AGENTS; DRUG DESIGN; EPOTHILONES; MICROTUBULE STABILIZERS; NATURAL PRODUCTS; TOTAL SYNTHESIS;

CHEMICAL MODIFICATION; DRUG DOSAGE; SYNTHESIS (CHEMICAL);

ENZYME INHIBITION;

EPOTHILONE DERIVATIVE; TUBULIN;

ARTICLE; CELL PROLIFERATION; CHEMISTRY; COMPARATIVE STUDY; CONFORMATION; DRUG EFFECT; DRUG SCREENING; HUMAN; METABOLISM; MICROTUBULE; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; EPOTHILONES; HUMANS; MICROTUBULES; MOLECULAR CONFORMATION; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TUBULIN;

EID: 28044438972     PISSN: 14337851     EISSN: None     Source Type: Journal    
DOI: 10.1002/anie.200501760     Document Type: Article

References (35)

1. M. C. Lu in Cancer Chemotherapeutic Agents (Ed.: W. O. Foye), American Chemical Society, Washington, DC, 1995, pp. 345-368.
2. E. Hamel, Med. Res. Rev. 1996, 16, 207-231.
3. E. K. Rowinsky, Annu. Rev. Med. 1997, 48, 353-374.
4. For recent reviews, see, for example: a) K.-H. Altmann, Curr. Opin. Chem. Biol. 2001, 5, 424-431;
5. b) D. C. Myles, Annu. Rep. Med. Chem. 2002, 37, 125-132.
6. For general reviews on the potential of natural-product-based libraries in lead discovery, see: a) R. Breinbauer, I. R. Vetter, H. Waldmann, Angew. Chem. 2002, 114, 3002-3015;
7. Angew. Chem. Int. Ed. 2002, 41, 2878-2890;
8. b) M. A. Koch, H. Waldmann, Drug Discovery Today 2005, 10, 471-483.
9. a) G. Höfle, N. Bedorf, K. Gerth, H. Reichenbach, German patent disclosure DE 4138042, May 5, 1993 (Priority Nov. 19, 1991);
10. b) K. Gerth, N. Bedorf, G. Höfle, H. Irschik, H. Reichenbach, J. Antibiot. 1996, 49, 560-564.
11. For reviews, see, for example: a) K.-H. Altmann, Curr. Pharm. Des. 2005, 11, 1595-1613;
12. b) K.-H. Altmann, Org. Biomol. Chem. 2004, 2, 2137-2152;
13. c) C. R. Harris, S. J. Danishefsky, J. Org. Chem. 1999, 64, 8434-8456;
14. d) K. C. Nicolaou, F. Roschangar, D. Vourloumis, Angew. Chem. 1998, 110, 2120-2153;
15. Angew. Chem. Int. Ed. 1998, 37, 2014-2045.
16. Epo C and Epo D are 12/13-deoxy derivatives of Epo A and Epo B, respectively; i.e., they incorporate a cis double bond between C12 and C13 instead of an epoxide moiety.
17. a) A. Rivkin, T.-C. Chou, S. J. Danishefsky, Angew. Chem. 2005, 117, 2898-2910;
18. Angew. Chem. Int. Ed. 2005, 44, 2838-2850;
19. b) A. Rivkin, F. Yoshimura, G. Fumihiko, A. E. Gabarda, Y. S. Cho, T.-C. Chou, H. Dong, S. J. Danishefsky, J. Am. Chem. Soc. 2004, 126, 10 913-10 922.
20. a) A. Regueiro-Ren, K. Leavitt, S.-H. Kim, G. Höfle, M. Kiffe, J. Z. Gougoutas, J. DiMarco, F. Y. F. Lee, C. R. Fairchild, B. H. Long, G. D. Vite, Org. Lett. 2002, 4, 3815-3818;
21. b) K.-H. Altmann, M. Wartmann, T. O'Reilly, Biochim. Biophys. Acta 2000, 1470, M79-M91.
22. T. Carlomagno, M. J. J. Blommers, J. Meiler, W. Jahnke, T. Schupp, F. Petersen, D. Schinzer, K.-H. Altmann, C. Griesinger, Angew. Chem. 2003, 115, 2619-2621;
23. Angew. Chem. Int. Ed. 2003, 42, 2511-2515.
24. a) K.-H. Altmann, G. Bold, G. Caravatti, D. Denni, A. Flörsheimer, A. Schmidt, G. Rihs, M. Wartmann, Helv. Chim. Acta 2002, 85, 4086-4110;
25. b) K.-H. Altmann, G. Bold, G. Caravatti, A. Flörsheimer, V. Guagnano, M. Wartmann, Bioorg. Med. Chem. Lett. 2000, 10, 2765-2768.
26. For the synthesis of 14, see ref. [12b]. The syntheses of 13 and 15 will be described elsewhere.
27. J. Rudolph, K. L. Reddy, J. P. Chang, K. B. Sharpless, J. Am. Chem. Soc. 1997, 119, 6189-6190.
28. M. Wartmann, K.-H. Altmann, A. Flörsheimer, unpublished data.
29. See also: a) K. C. Nicolaou, K. Namoto, A. Ritzen, T. Ulven, M. Shoji, J. Li, G. D'Amico, D. Liotta, C. T. French, M. Wartmann, K.-H. Altmann, P. Giannakakou, J. Am. Chem. Soc. 2001, 123, 9313-9323;
30. b) K. C. Nicolaou, N. Winssinger, J. Pastor, S. Ninkovic, F. Sarabia, Y. He, D. Vourloumis, Z. Yang, T. Li, P. Giannakakou, E. Hamel, Nature 1997, 387, 268-272.
31. Z.-X. Wang, Y. Tu, M. Frohn, J.-R. Zhang, Y. Shi, J. Am. Chem. Soc. 1997, 119, 11 224-11 235.
32. C. M. Lin, Y. Q. Jiang, A. G. Chaudhary, J. M. Rimoldi, D. G. Kingston, E. Hamel, Cancer Chemother. Pharmacol. 1996, 38, 136-140.
33. a) T. Meyer, U. Regenass, D. Fabbro, E. Alteri, J. Rösel, M. Müller, G. Caravatti, A. Matter, Int. J. Cancer 1989, 43, 851-856;
34. b) K. C. Nicolaou, R. Scarpelli, B. Bollbuck, B. Werschkun, M. M. Pereira, M. Wartmann, K.-H. Altmann, D. Zaharevitz, R. Gussio, P. Giannakakou, Chem. Biol. 2000, 7, 593-599.
35. Structural similarity was assessed on the basis of Tanimoto coefficients (i.e., by a simple 2D fragment-based approach; see, for example: X. Chen, C. H. Reynolds, J. Chem. Inf. Comput. Sci. 2002, 42, 1407-1014). Similarity analyses using other approaches are currently underway, and the results of these studies will be published elsewhere.